{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:03Z","timestamp":1781639703358,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["SPHeRE 3 2022\/1"],"award-info":[{"award-number":["SPHeRE 3 2022\/1"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic nonmalignant pain (CNMP) is commonly treated with opioids and other analgesics, yet prescribing carries risks and substantial costs. Promotional and financial interactions between clinicians and the pharmaceutical industry may influence analgesic prescribing, but CNMP-relevant evidence has not been systematically synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, EMBASE, CINAHL, PsycINFO, and Web of Science from inception to February 2025 (no language restrictions). We included observational studies assessing associations between pharmaceutical industry interactions and analgesic prescribing outcomes relevant to CNMP. Two reviewers independently screened studies, extracted data, assessed risk of bias using ROBINS\u2011I, and appraised certainty using GRADE. We synthesized findings using SWiM vote counting by direction of effect, and undertook random\u2011effects meta\u2011analysis when exposure and outcome definitions were sufficiently similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten U.S. observational studies met inclusion criteria. Across 44 outcome contrasts, 38 (86%) were directed towards higher prescribing or higher opioid\u2011related expenditure among clinicians receiving payments\/interactions; 6 contrasts evaluating marketing\u2011restriction policies were directed towards reduced prescribing. Because prescribing\u2011volume metrics were heterogeneous (e.g., prescriptions vs. days supplied), we did not pool volume outcomes. For expenditure, meta\u2011analysis of two studies showed that receipt of opioid\u2011related payments was associated with higher opioid\u2011related prescribing expenditure (pooled +$4,785 per physician\u2011year; 95% CI $2,162 to $7,408; I\u00b2 = 93.5%). Under ROBINS\u2011I, studies were at low to moderate overall risk of bias, with residual confounding a key concern. GRADE certainty was moderate for prescribing expenditure and prescribing volume and low for dosage intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In U.S. real-world prescribing datasets, pharmaceutical industry interactions were consistently associated with higher analgesic prescribing and higher opioid-related expenditures, with repeated evidence of dose\u2013response patterns. Evidence from institutional restriction policies suggests prescribing may be modifiable when promotional access is constrained. However, the evidence is observational and largely does not identify CNMP patients explicitly; residual confounding and indirectness should be considered when interpreting magnitude.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42024627184.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-026-00734-z","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:34:55Z","timestamp":1772699695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations between pharmaceutical industry interactions with physicians and chronic nonmalignant pain management prescribing practices: a systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Mohammed","family":"Gharbia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Iladiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"3","key":"734_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.7326\/M20-5665","volume":"174","author":"AP Mitchell","year":"2021","unstructured":"Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, Diaz LA Jr, Korenstein D. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. Ann Intern Med. 2021;174(3):353\u201361.","journal-title":"Ann Intern Med"},{"issue":"8","key":"734_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","volume":"176","author":"C DeJong","year":"2016","unstructured":"DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114\u201322.","journal-title":"JAMA Intern Med"},{"key":"734_CR3","doi-asserted-by":"publisher","first-page":"1072708","DOI":"10.3389\/fpubh.2022.1072708","volume":"10","author":"E Zarei","year":"2023","unstructured":"Zarei E, Ghaffari A, Nikoobar A, Bastami S, Hamdghaddari H. Interaction between physicians and the pharmaceutical industry: a scoping review for developing a policy brief. Front Public Health. 2023;10:1072708.","journal-title":"Front Public Health"},{"issue":"6","key":"734_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1215\/03616878-10041205","volume":"47","author":"A Mitchell","year":"2022","unstructured":"Mitchell A, Sarpatwari A, Bach PB. Industry payments to physicians are kickbacks. How should stakeholders respond? J Health Polit Policy Law. 2022;47(6):815\u201333.","journal-title":"J Health Polit Policy Law"},{"key":"734_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-018-3043-8","volume":"18","author":"M Sharma","year":"2018","unstructured":"Sharma M, Vadhariya A, Johnson ML, Marcum ZA, Holmes HM. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data. BMC Health Serv Res. 2018;18:1\u20138.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"734_CR6","doi-asserted-by":"publisher","first-page":"e0175493","DOI":"10.1371\/journal.pone.0175493","volume":"12","author":"H Brax","year":"2017","unstructured":"Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, Akl EA. Association between physicians\u2019 interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis. PLoS ONE. 2017;12(4):e0175493.","journal-title":"PLoS ONE"},{"issue":"7","key":"734_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/pds.4224","volume":"26","author":"J Qian","year":"2017","unstructured":"Qian J, Hansen RA, Surry D, Howard J, Kiptanui Z, Harris I. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing. Pharmacoepidemiol Drug Saf. 2017;26(7):819\u201326.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"734_CR8","doi-asserted-by":"publisher","first-page":"e20231317","DOI":"10.1590\/1806-9282.20231317","volume":"70","author":"GR Gameiro","year":"2024","unstructured":"Gameiro GR, Gameiro GR, Silva RM, Guilloux AG, Cassenote AJ, Scheffer MC. Physician\u2019s perceptions regarding the pharmaceutical industry: a Brazilian national study. Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira. 2024;70(5):e20231317.","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000079063","volume":"25","author":"Y Olsen","year":"2004","unstructured":"Olsen Y, Daumit GL. Opioid prescribing for chronic nonmalignant pain in primary care: challenges and solutions. Adv Psychosom Med. 2004;25:138\u201350. (9).","journal-title":"Adv Psychosom Med"},{"issue":"1","key":"734_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/pharmacy4010015","volume":"4","author":"MC Kennedy","year":"2016","unstructured":"Kennedy MC, Henman MC, Cousins G. General practitioners and chronic non-malignant pain management in older patients: a qualitative study. Pharmacy. 2016;4(1):15.","journal-title":"Pharmacy"},{"issue":"2","key":"734_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","volume":"152","author":"KM Dunn","year":"2010","unstructured":"Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Overdose and prescribed opioids: Associations among chronic non-cancer pain patients. Ann Intern Med. 2010;152(2):85.","journal-title":"Ann Intern Med"},{"issue":"7","key":"734_CR12","doi-asserted-by":"publisher","first-page":"e0307701","DOI":"10.1371\/journal.pone.0307701","volume":"19","author":"L Rufener","year":"2024","unstructured":"Rufener L, Akre C, Rodondi PY, Dubois J. Management of chronic non-cancer pain by primary care physicians: A qualitative study. PLoS ONE. 2024;19(7):e0307701.","journal-title":"PLoS ONE"},{"key":"734_CR13","doi-asserted-by":"publisher","first-page":"732345","DOI":"10.3389\/fphar.2021.732345","volume":"12","author":"A Kurdi","year":"2021","unstructured":"Kurdi A. Opioids and gabapentinoids utilisation and their related-mortality trends in the United Kingdom primary care setting, 2010\u20132019: a cross-national, population-based comparison study. Front Pharmacol. 2021;12:732345.","journal-title":"Front Pharmacol"},{"key":"734_CR14","doi-asserted-by":"publisher","DOI":"10.17226\/24781","volume-title":"Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use","year":"2017","unstructured":"Phillips JK, Ford MA, Bonnie RJ, editors. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC): National Academies Press (US); 2017. https:\/\/doi.org\/10.17226\/24781."},{"key":"734_CR15","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"key":"734_CR16","doi-asserted-by":"crossref","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368.","DOI":"10.1136\/bmj.l6890"},{"key":"734_CR17","doi-asserted-by":"crossref","unstructured":"Gharbia M, Larkin J, Moriarty F, Fahey T. Associations between pharmaceutical industry interactions and prescribing practices in chronic non-malignant pain management: a systematic review. PROSPERO. 2024. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024627184","DOI":"10.12688\/hrbopenres.14071.1"},{"key":"734_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12688\/hrbopenres.14071.1","volume":"8","author":"M Gharbia","year":"2025","unstructured":"Gharbia M, Iladiva L, Moriarty F, Fahey T, Larkin J. Associations between pharmaceutical industry interactions and prescribing practices in chronic non-malignant pain management: A protocol for a systematic review. HRB Open Res. 2025;8:15.","journal-title":"HRB Open Res"},{"key":"734_CR19","unstructured":"Covidence [Internet]. Melbourne (Australia): Veritas Health Innovation; Available from: https:\/\/www.covidence.org\/"},{"key":"734_CR20","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.","DOI":"10.1136\/bmj.i4919"},{"key":"734_CR21","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook"},{"key":"734_CR22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s11606-019-04897-9","volume":"34","author":"W Fleischman","year":"2019","unstructured":"Fleischman W, Agrawal S, Gross CP, Ross JS. Association of pharmaceutical manufacturer payments to physicians and prescribing dosage of opioids. J Gen Intern Med. 2019;34:1074\u20136.","journal-title":"J Gen Intern Med"},{"key":"734_CR23","first-page":"15","volume":"2013","author":"HJ Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann HJ, Bro\u017cek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated Oct. 2013;2013:15.","journal-title":"Updated Oct"},{"issue":"12","key":"734_CR24","doi-asserted-by":"publisher","first-page":"e0209383","DOI":"10.1371\/journal.pone.0209383","volume":"13","author":"MA Zezza","year":"2018","unstructured":"Zezza MA, Bachhuber MA. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing. PLoS ONE. 2018;13(12):e0209383.","journal-title":"PLoS ONE"},{"issue":"6","key":"734_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/add.14509","volume":"114","author":"TD Nguyen","year":"2019","unstructured":"Nguyen TD, Bradford WD, Simon KI. Pharmaceutical payments to physicians may increase prescribing for opioids. Addiction. 2019;114(6):1051\u20139.","journal-title":"Addiction"},{"issue":"12","key":"734_CR26","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/hec.4424","volume":"30","author":"S Beilfuss","year":"2021","unstructured":"Beilfuss S, Linde S. Pharmaceutical opioid marketing and physician prescribing behavior. Health Econ. 2021;30(12):3159\u201385.","journal-title":"Health Econ"},{"issue":"10","key":"734_CR27","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jamainternmed.2019.1082","volume":"179","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Ross JS. Association between industry payments to physicians and gabapentinoid prescribing. JAMA Intern Med. 2019;179(10):1425\u20138.","journal-title":"JAMA Intern Med"},{"key":"734_CR28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s11606-019-05470-0","volume":"35","author":"MA Hollander","year":"2020","unstructured":"Hollander MA, Donohue JM, Stein BD, Krans EE, Jarlenski MP. Association between opioid prescribing in Medicare and pharmaceutical company gifts by physician specialty. J Gen Intern Med. 2020;35:2451\u20138.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"734_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1377\/hlthaff.2019.01289","volume":"39","author":"MD Eisenberg","year":"2020","unstructured":"Eisenberg MD, Stone EM, Pittell H, McGinty EE. The Impact Of Academic Medical Center Policies Restricting Direct-To-Physician Marketing On Opioid Prescribing: Study examines opioid prescribing by physicians at academic medical centers where conflict-of-interest policies restrict pharmaceutical companies from marketing all drugs directly to physicians. Health Aff. 2020;39(6):1002\u201310.","journal-title":"Health Aff"},{"issue":"13","key":"734_CR30","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s11606-022-07457-w","volume":"37","author":"E Pope","year":"2022","unstructured":"Pope E, Sehgal N. Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D. J Gen Intern Med. 2022;37(13):3509\u201311.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"734_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jamainternmed.2018.1999","volume":"178","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Cerd\u00e1 M, Li Y, Krieger MS, Marshall BD. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern Med. 2018;178(6):861\u20133.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"734_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/jech-2020-214021","volume":"74","author":"K Inoue","year":"2020","unstructured":"Inoue K, Figueroa JF, Orav EJ, Tsugawa Y. Association between industry payments for opioid products and physicians\u2019 prescription of opioids: observational study with propensity-score matching. J Epidemiol Community Health. 2020;74(8):647\u201354.","journal-title":"J Epidemiol Community Health"},{"key":"734_CR33","doi-asserted-by":"crossref","unstructured":"Dowell D. CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022. MMWR. Recommendations and reports. 2022;71.","DOI":"10.15585\/mmwr.rr7103a1"},{"issue":"5","key":"734_CR34","doi-asserted-by":"publisher","first-page":"e0155474","DOI":"10.1371\/journal.pone.0155474","volume":"11","author":"RH Perlis","year":"2016","unstructured":"Perlis RH, Perlis CS. Physician payments from industry are associated with greater Medicare Part D prescribing costs. PLoS ONE. 2016;11(5):e0155474.","journal-title":"PLoS ONE"},{"issue":"15","key":"734_CR35","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016;315(15):1624\u201345.","journal-title":"JAMA"},{"issue":"4","key":"734_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/M14-2559","volume":"162","author":"R Chou","year":"2015","unstructured":"Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276\u201386.","journal-title":"Ann Intern Med"},{"issue":"6","key":"734_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2016.1709","volume":"176","author":"JS Yeh","year":"2016","unstructured":"Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med. 2016;176(6):763\u20138.","journal-title":"JAMA Intern Med"},{"issue":"17","key":"734_CR38","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.2017.3091","volume":"317","author":"KR Tringale","year":"2017","unstructured":"Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and distribution of payments from industry to physicians in 2015. JAMA. 2017;317(17):1774\u201384.","journal-title":"JAMA"},{"issue":"17","key":"734_CR39","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1056\/NEJMsa064508","volume":"356","author":"EG Campbell","year":"2007","unstructured":"Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician\u2013industry relationships. N Engl J Med. 2007;356(17):1742\u201350.","journal-title":"N Engl J Med"},{"issue":"3","key":"734_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jama.283.3.373","volume":"283","author":"A Wazana","year":"2000","unstructured":"Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373\u201380.","journal-title":"JAMA"},{"issue":"10","key":"734_CR41","doi-asserted-by":"publisher","first-page":"e1000352","DOI":"10.1371\/journal.pmed.1000352","volume":"7","author":"GK Spurling","year":"2010","unstructured":"Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI. Information from pharmaceutical companies and the quality, quantity, and cost of physicians\u2019 prescribing: a systematic review. PLoS Med. 2010;7(10):e1000352.","journal-title":"PLoS Med"},{"key":"734_CR42","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.jhealeco.2024.102887","volume":"95","author":"M Newham","year":"2024","unstructured":"Newham M, Valente M. The cost of influence: how gifts to physicians shape prescriptions and drug costs. J Health Econ. 2024;95:102887.","journal-title":"J Health Econ"},{"issue":"10","key":"734_CR43","first-page":"669","volume":"36","author":"CL Ventola","year":"2011","unstructured":"Ventola CL. Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? Pharm Ther. 2011;36(10):669.","journal-title":"Pharm Ther"},{"key":"734_CR44","unstructured":"Centers for Medicare & Medicaid Services. Open Payments \u2013 About the program [Internet]. Baltimore (MD): CMS. Available from: https:\/\/openpaymentsdata.cms.gov\/"},{"key":"734_CR45","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Code of Practice [Internet]. Brussels: EFPIA. 2023. Available from: https:\/\/www.efpia.eu\/"},{"issue":"12","key":"734_CR46","doi-asserted-by":"publisher","first-page":"e053138","DOI":"10.1136\/bmjopen-2021-053138","volume":"11","author":"P Ozieranski","year":"2021","unstructured":"Ozieranski P, Martinon L, Jachiet PA, Mulinari S. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ open. 2021;11(12):e053138.","journal-title":"BMJ open"},{"key":"734_CR47","unstructured":"Accreditation Council for Continuing Medical Education (ACCME). Standards for Integrity and Independence in Accredited Continuing Education [Internet]. 2020. Available from: https:\/\/www.accme.org\/"},{"key":"734_CR48","doi-asserted-by":"publisher","unstructured":"Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice; Lo B, Field MJ, editors. Conflict of Interest in Medical Research, Education, and Practice. Washington (DC): National Academies Press (US); 2009. https:\/\/doi.org\/10.17226\/12598","DOI":"10.17226\/12598"},{"issue":"4","key":"734_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jama.295.4.429","volume":"295","author":"TA Brennan","year":"2006","unstructured":"Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, Smelser N. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295(4):429\u201333.","journal-title":"JAMA"},{"issue":"7","key":"734_CR50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11606-017-4012-3","volume":"32","author":"G Pham-Kanter","year":"2017","unstructured":"Pham-Kanter G, Mello MM, Lehmann LS, Campbell EG, Carpenter D. Public awareness of and contact with physicians who receive industry payments: a national survey. J Gen Intern Med. 2017;32(7):767\u201374.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"734_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jamainternmed.2019.6544","volume":"180","author":"JC Montoy","year":"2020","unstructured":"Montoy JC, Coralic Z, Herring AA, Clattenburg EJ, Raven MC. Association of default electronic medical record settings with health care professional patterns of opioid prescribing in emergency departments: a randomized quality improvement study. JAMA Intern Med. 2020;180(4):487\u201393.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"734_CR52","doi-asserted-by":"publisher","first-page":"e217481","DOI":"10.1001\/jamanetworkopen.2021.7481","volume":"4","author":"MA Bachhuber","year":"2021","unstructured":"Bachhuber MA, Nash D, Southern WN, Heo M, Berger M, Schepis M, Thakral M, Cunningham CO. Effect of changing electronic health record opioid analgesic dispense quantity defaults on the quantity prescribed: a cluster randomized clinical trial. JAMA Netw Open. 2021;4(4):e217481.","journal-title":"JAMA Netw Open"},{"key":"734_CR53","unstructured":"Centers for Disease Control and Prevention. Electronic clinical decision support tools for safer opioid prescribing [Internet]. 2024. Available from: https:\/\/www.cdc.gov\/"},{"key":"734_CR54","doi-asserted-by":"publisher","first-page":"104402","DOI":"10.1016\/j.jpubeco.2021.104402","volume":"197","author":"C Carey","year":"2021","unstructured":"Carey C, Lieber EM, Miller S. Drug firms\u2019 payments and physicians\u2019 prescribing behavior in Medicare Part D. J Public Econ. 2021;197:104402.","journal-title":"J Public Econ"},{"key":"734_CR55","doi-asserted-by":"publisher","unstructured":"Grainger MJ, Stewart GB, Haddaway NR. Why \u201cvote-counting\u201d is never acceptable in evidence synthesis. Preprint. 2022. https:\/\/doi.org\/10.31219\/osf.io\/c49uh","DOI":"10.31219\/osf.io\/c49uh"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00734-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00734-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00734-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:23:57Z","timestamp":1781637837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00734-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00734-z","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of published literature and did not involve human participants, human tissue, or identifiable personal data; therefore, no ethics committee approval or participant consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"HRB Open Research, 2025.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}